Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood protein may reveal how active behçet disease is

NCT ID NCT07803198

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are testing whether blood levels of a protein called asprosin are higher or lower in people with Behçet disease, and whether those levels match how active the disease is. The study will enroll 44 adults who meet the international criteria for Behçet disease. No treatment is given. The goal is to see if asprosin could serve as a biomarker for disease activity and major symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No intervention is given. This observational study measures blood levels of the protein asprosin.
What this could lead to
If asprosin levels track with disease activity, it could become a simple blood test to help monitor Behçet disease.
What could go wrong
This is a small, early study that only looks for a link. It cannot prove asprosin causes symptoms or that a test will work in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include adult patients with Behçet's disease fulfilling the International Criteria for Behçet's Disease (ICBD), as well as age- and sex-matched healthy controls. Patients will be recruited from the Rheumatology Department. The study will assess serum Asprosin levels in relation to disease activity in Behçet's disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects (≥ 18 years) satisfying the International Criteria for Behçet's Disease (ICBD) will be included in \[7\]. Exclusion Criteria: * Patients with other autoimmune diseases. * Patients with Acute inflammatory condition at the time of blood sampling. * Pregnant participants, and participants with active infection, known malignancy, diabetes mellitus, chronic kidney or liver disease, thyroid or other endocrine disorders, obesity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Behcet disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behcet disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Behcet disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.